Introduction
The A33 antigen is a membrane-bound glycoprotein (Catimel et al., 1996; Heath et al., 1997) . Like other trans-membrane proteins, A33 antigen possesses three distinct regions: an extracellular region containing two putative immunoglobulin-like domains, a hydrophobic trans-membrane region, and a highly polar intracellular region containing four consecutive cysteine residues. Based on its amino-acid sequence and genomic structure, the A33 antigen is considered to be a member of a growing subfamily within the immunoglobulin superfamily that includes the marker of cortical thymocytes in Xenopus (CTX) (Chretien et al., 1996) , its putative chicken ortholog ChT1 (Katevuo et al., 1999) , mouse and human homologs of CTX (CTM/CTH) (Chretien et al., 1998) , and the receptor for group B Coxsackie viruses and adenoviruses types 2 and 5 (CAR) (Bergelson et al., 1997 (Bergelson et al., , 1998 Tomko et al., 1997) .
The biological function of A33 antigen is not yet understood. It has been suggested that the A33 antigen may be a novel cell surface receptor or cell adhesion molecule in the immunoglobulin superfamily (Heath et al., 1997) . Immunohistochemical studies of normal tissues identified the large and small intestinal mucosa as the principal site of A33 antigen expression (Sakamoto et al., 2000) . Tests in tumor samples demonstrated that only tumors of the gastrointestinal tract are consistently A33 antigen positive (Sakamoto et al., 2000) .
The highly tissue-specific expression of A33 antigen presents a great opportunity for specific tumor targeting in patients with gastrointestinal cancer. Studies using nude mouse models with xenografts of the human colorectal carcinoma cell line SW1222 indicated that an A33 monoclonal antibody (mAb) was capable of inducing tumor regression (Antoniw et al., 1996) . In phase I and II trials, 131 I-and 125 I-labeled murine A33 mAb were shown to have antitumor effects without bowel toxicity (Welt et al., 1994 . A genetically humanized mAb A33 has been generated and phase I trials have been undertaken . However, the mechanism responsible for the tissue-specific pattern of its expression is not yet understood.
Gut-enriched Kru¨ppel-like factor (GKLF) is a member of the Kru¨ppel-like factor (KLF) family that function as zinc-finger-containing transcription factors. The expression of GKLF is enriched in epithelial cells of the gastrointestinal tract (Ton-That et al., 1997; Behr and Kaestner, 2002) and the skin (Behr and Kaestner, 2002) and in vascular endothelial cells (Yet et al., 1998; McCormick et al., 2001; Gray et al., 2002; Nickenig et al., 2002) . Phylogenetically and structurally, KLFs are closely related to Sp1 and Krox transcription factors and they recognize very similar 'GT-box' or 'CACCC element' sites on DNA (Mahatan et al., 1999; Black et al., 2001) .
The biological functions of GKLF are not entirely clear. In vitro studies have suggested that GKLF plays an important role in cell proliferation and/or differentiation (Shie et al., 2000b) . However, gene ablation in mice leads to a specific deficiency in the barrier function of the skin, resulting in postnatal death. Further, the extent of normal development seen in its absence is interesting given the expression pattern and postulated role of GKLF in the intestine and other endodermal tissues (Katz et al., 2002) . In addition, although a negative correlation is seen between GKLF level and growth in intestinal and prostatic carcinomas (Foster et al., 2000) , GKLF levels are upregulated during progression of human oral/pharyngeal and breast carcinomas (Foster et al., 2000) .
Here we demonstrate that GKLF is a critical factor in contributing to the expression of A33 antigen in colonic carcinoma cells. Given the clinical observations that 131 Iand I25 I-labeled murine A33 mAb lead to the regression of colonic tumors, our results suggest that GKLF plays a more diverse role in the intestine than as a regulator in mediating cell growth arrest and differentiation.
Results

Cloning and analysis of the 5
0 -flanking region of the human A33 gene
In order to understand the molecular mechanisms involved in the regulation of A33 antigen expression, we first cloned the 5 0 -flanking region of the A33 antigen gene by PCR using the library provided in the Genome Walker Kit (Clontech). An B1 kb PCR product was obtained and sequenced in both directions using the automated ABI Prism 370 Sequencer. Analysis of this sequence indicated that it contains a canonical TATA box, two MRE (metal response element), as well as putative binding sites for C/EBP (CCAAT enhancer binding protein), GKLF, and CDX (caudal-related homeobox) (Figure 1a) . Primer extension experiments with total RNA from LoVo cells produced a major band of about 248 bp (Figure 1b) , indicating that the transcription starting site is 10 nucleotides downstream of the TATA box ( Figure 1c) . As a control, primer extensions using tRNA did not result in any bands (data not shown).
Identification of cis-elements involved in the regulation of A33 expression in gastrointestinal carcinoma cells
To determine the transcription activation activity of the obtained DNA sequence, we next constructed EGFP reporter constructs with the B1 kb fragment as well as with the fragments from À759 to þ 25, À518 to þ 25, À189 to þ 25, and À104 to þ 25 of the cloned sequence by nested PCR reactions. Transient transfections were then carried out to map the cis-elements involved in the regulation of A33 antigen gene expression. Cells from LoVo (colonic carcinoma cell line), BGC823 (gastric carcinoma cell line), and 293 (kidney carcinoma cell line) were grown in DMEM supplemented with 10% fetal bovine serum for 24 h and transfected with the A33 antigen gene 5 0 -flanking region-driven EGFP reporter construct. Cells were then lysed and analysed for EGFP activity. In accordance with the tissue-specific pattern of expression of A33 antigen (Abud et al., 2000; Sakamoto et al., 2000) , the A33 antigen promoter fragments were highly active in the human colon carcinoma cell line LoVo (Figure 2 ), somewhat active in BGC 823 cells, and not active in 293 cells. In addition, the EGFP activation was A33 antigen gene promoterspecific since the promoter-less vector showed low activation of EGFP expression. Serial deletion of the 5 0 -flanking region of the A33 antigen gene up to position À104 did not affect the transcriptional activation of EGFP expression (Figure 2 ), suggesting that the ciselement(s) for regulating the expression of the A33 antigen in colonic carcinoma cells resides in the region of À104 to þ 25.
DNase I footprinting analysis of A33 5 0 -flanking region
To identify the cis-elements within the À104 to þ 25 region, DNase I footprinting analysis was performed using nuclear extracts from LoVo cells. As shown in Figure 3 , two DNase I-protected regions, designated as sites A and B, were detected on both strands of this fragment by footprinting. Site A extends from À68 to À86 and covers the sequence 5 0 -ACACCCTTCTTT-TACTAG-3 0 . Analysis of this sequence identified a recognition site for GKLF. Site B spans from À40 to À19 and covers the sequence 5 0 -CCCTTTTTATTATT-TATTTCCT-3 0 . A CDX-binding sequence was identified and the binding of CDX1 was demonstrated in this site in a recent report by Johnstone et al. (2002) . DNase I footprinting experiments were also done using nuclear extracts from 293 cells. In agreement with our finding of no transcription activation activity in transient tranfection assays in 293 cells (Figure 2 ), the sequence from À104 to þ 25 was not protected by nuclear extracts from 293 cells (data not shown), suggesting that the transcription activity coincides with the binding of transcription factor in this region.
Site-directed mutagenesis in sites A and B
In order to confirm the functional significance of sites A and B to the promoter activity of the A33 antigen, sitedirected mutagenesis was carried out to change nucleotides CC at positions À81 and À82 in site A to AG and to change nucleotides TAT at positions À28 to À30 in site B to CGA. Transient transfection experiments were performed to assess the effect of these mutations on the transcription activation activity of the À104 to þ 25 fragment. As shown in Figure 4 , mutation in either site A or site B resulted in a significant decrease in the promoter activity of this fragment, suggesting that both sites are essential for the transcription activation activity of this fragment.
Identification of trans-acting factors
Next, we performed electrophoretic mobility shift assays (EMSA) to determine the binding of protein factors in the fragment À104 to þ 25. Double-stranded synthetic oligonucleotides named probes A and B (see details under the Materials and methods) encompassing each of the two DNase I footprinted sites were used as probes and incubated with nuclear extracts from LoVo, BGC823, and 293 cells. As shown in Figure 5a (upper To identify the protein factor(s) bound to probe A, a super-shift experiment was performed. Based on the presence of a putative GKLF binding site in this sequence, anti-GKLF antibodies were incubated with LoVo cell nuclear extracts followed by the addition of labeled probe A. As shown in Figure 5b , addition of the GKLF antibody caused a super-shift of the DNAprotein complex (Figure 5b , lane 2), indicating that the probe contains a GKLF binding site. The probe B contains a CDX-binding sequence and was demonstrated to be able to interact with CDX1 in a recent report by Johnstone et al. (2002) .
Regulation of A33 expression by GKLF
To test the hypothesis that GKLF might contribute to the tissue-specific expression of the A33 antigen, we first examined the expression of GKLF and A33 antigen in LoVo, BGC823, and 293 cells by Northern blotting and RT-PCR. As shown in Figure 6a , the GKLF mRNA expression was high in LoVo cells, low in BGC823 cells, and undetectable in 293 cells. Interestingly, a similar pattern of expression was also observed for A33 antigen (Figure 6b ). These data agree well with the data observed in the reporter experiments described in Figure 2 , in fingerprinting experiments described in Figure 5 DNA-protein interactions in the two DNase I-protected regions. (a) Electrophoretic mobility shift assays were performed using radiolabeled oligonucleotides containing either the footprinted site A (probe A, upper panel) or site B (probe B) and cell nuclear extracts. A total of 1 ng of radiolabeled oligonucleotides and 10 mg of nuclear extracts from LoVo, BGC823, or 293 cells were used in each reaction. Lane 1 contains the free probe only; lanes 2, 5, and 8 contain labeled probe and nuclear extracts; lanes 3, 6, and 9 contain labeled probe, nuclear extract, and unlabeled probe; lane 4, 7, and 10 contain labeled probe, nuclear extracts, and an unrelated DNA fragment. (b) Supershift assays were performed with nuclear extracts from LoVo cells and the oligonucleotide probe containing GKLF binding site in the absence (lane 1) or the presence of GKLF antibody (lane 2). The arrows indicate the free probes (Figure 7a , lower panel, lane 1), however, the A33 antigen gene promoter was activated (Figure 7a, upper panel) . Next, we utilized an antisense approach to inhibit the expression of GKLF in LoVo cells and the transcription activation activity of the A33 antigen gene promoter was assessed by transient transfection experiments. As shown in Figure 7b and c, after inhibition of the GKLF expression by its antisense (AS) (Figure 7b , middle panel), the activity of A33 antigen gene promoter was effectively inhibited only in LoVo cells (Figure 7b , upper panel, and Figure 7c ). The effects on the A33 antigen promoter were not because of the transfection efficiency as the expression levels of a co-transfected Lac Z construct in all the experiments were similar (Figure 7b , lower panel). Collectively, these data indicate that GKLF is an essential transcription factor that contributes to the tissue-specific expression of the A33 antigen.
Discussion
A33 antigen is a highly tissue-specific gene with expression found primarily in gastrointestinal epithelia. Although A33 antigen is being investigated as a potential target for immunotherapy of colon cancer (Welt et al., 1994 King et al., 1995; Antoniw et al., 1996; Barendswaard et al., 2001 ), a basic understanding of the mechanisms underlying its tightly regulated tissue-specific expression is lacking. Such knowledge is likely to shed light on the biological functions of A33 antigen and thus its roles in colon cancer carcinogenesis. In this paper, we report on the cloning and characterization of the 5 0 -flanking region of the human A33 antigen gene. The sequence of the 5 0 -flanking region of the human A33 gene contains a typical TATA box. The major start site for transcription was determined to be 10 nucleotides downstream of the TATA sequence, which is consistent with the recent finding by Johnstone et al. (2002) . However, the transcription of the A33 antigen gene might not be TATA-dependent as suggested by Johnstone et al. (2002) , since most of TATA boxes are located 25-30 bp upstream of the initiation of transcription. Functional analysis by transient transfections showed that the promoter for human A33 antigen gene is most active in intestinal cells, less active in gastric cells, and not active in 293 cells, which is consistent with the expression pattern of the A33 gene in these cells. Serial deletion analysis revealed that the proximal region of the promoter (positions À104 to þ 25) was sufficient to generate maximal activity of the promoter in LoVo cells. Two protected sites in the proximal promoter region were subsequently identified by using the DNase I footprinting assay. Both sites are required for promoter activity since mutations in either site led to a significant decrease in promoter activity. Electrophoretic mobility shift assays identified one site, site A, which is bound by transcription factor GKLF, and the other site, site B, as recently reported by Johnstone et al. (2002) to harbor a CDX-binding site. The biological connection between GKLF binding in the A33 antigen gene promoter and the expression of A33 antigen is evident as blocking the expression of GKLF in GKLFpositive LoVo cells abolished the expression of the A33 antigen. Collectively, these data indicate that GKLF contributes to the tissue-specific expression of A33 antigen. It will be interesting in the future investigation to explore the relation between GKLF and CDX1 transcription factors in the regulation of the A33 antigen expression as CDX1 was also identified as a critical factor in contributing to the tissue-specific expression of the A33 antigen. It could be that both GKLF and CDX1 are necessary but not sufficient in regulating the tissue-specific expression of the A33 antigen, and it is intriguing to speculate that there is another yet unidentified protein factor or protein factors that serve as a coactivator(s) in coordinating the transcription activation of the A33 antigen gene.
GKLF is a Kru¨ppel-type zinc-finger transcription factor (Shields et al., 1996; Yet et al., 1998; Mahatan et al., 1999; Katz et al., 2002) . Expression of GKLF is enriched in epithelial cells of the gastrointestinal tract (Ton-That et al., 1997; Behr and Kaestner, 2002) and the skin (Ton-That et al., 1997) and in vascular endothelial cells (Yet et al., 1998; McCormick et al., 2001; Gray et al., 2002) . GKLF has been investigated with respect to its role in cellular differentiation, initially within the gastrointestinal tract and in the epidermis where GKLF is critical for late-stage differentiation of skin cells (Ohnishi et al., 2000; Behr and Kaestner, 2002) . GKLF has been shown to contain a transcription activation domain as well as a transcription repression domain (Yet et al., 1998; Zhang et al., 1998 Zhang et al., , 2000 Shie et al., 2000a; Chen et al., 2002) . It was observed that the p21 promoter contains CACCC elements, and GKLF was shown to bind and directly transactivate the p21 promoter via these sites (Zhang et al., 2000) . The induction of p21 was dependent on p53 and thus also occurred after DNA damage with methyl methanesulfonate. In addition, GKLF physically interacts with p53 (Zhang et al., 2000) . The resultant synergistic induction by p53 and GKLF of p21 then leads to its inhibition of cyclin-dependent kinases and subsequent growth arrest. In keratinocytes, GKLF activates the keratin 4 promoter and may be implicated in the transition toward cell differentiation (Jenkins et al., 1998; Okano et al., 2000) . GKLF has also been shown to upregulate the expression of keratin 19 (Brembeck and Rustgi, 2000) and laminin a3A (Miller et al., 2001) . On the other hand, GKLF has also been found to inhibit gene transcription by competing for the binding site with Sp1 (Zhang et al., 1998; Shie et al., 2000a) or by interacting with/ sequestering p300/CBP . It was also shown that the minimal cyclin D1 promoter contains multiple CACCC elements that bind GKLF in vitro and that GKLF binding results in in vivo repression of the promoter, an effect not seen after transfection of Sp1. Together, these data argue that GKLF plays a critical role in the decision between proliferation and cell cycle arrest/differentiation and they suggest that GKLF is a pleiotropic (activating and repressive) transcription factor. Our studies demonstrated that GKLF upregulates the expression of A33 antigen in colonic carcinoma cells. Although the biological functions of the A33 antigen is currently not understood, targeting A33 antigen by its antibody led to the growth inhibition of colon carcinomas, suggesting that A33 antigen is involved in cell growth and proliferation (Welt et al., 1994 Antoniw et al., 1996) . Hence our results showing that A33 is a downstream target of GKLF suggest that GKLF plays more complex and diverse roles in the intestine.
Materials and methods
Cell lines and reagents
All chemicals were from Sigma (St Louis, MO, USA) unless otherwise noted. The human cell lines LoVo, BGC823, and 293 were from ATCC (Manassas, VA, USA). Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum, and the TOPO2.1 T/A cloning vector were from Invitrogen (Carlsbad, CA, USA). All restriction enzymes were either from New England Biolab (Beverly, MA, USA) or Promega (Madison, WI, USA).
Cloning of the 5
0 -flanking region of human A33 antigen gene
The 5 0 -flanking region of the human A33 gene was cloned using a Genome Walker Kit from Clontech (Palo Alto, CA, USA) according to the manufacturer's instructions. PCR primer sequences used for cloning were: forward, 5 0 -AC-CTCCCCTGCCTTCTCCCTACTTA-3 0 , and reverse, 5 0 -TCCTAGACTGCTCACAAAGGGGTA-3
0 . An B1 kb band from the PCR reaction was extracted and purified with QIAquick Gel Extraction kit (Qiagen, Valencia, CA, USA) and cloned into the TOPO2.1 T/A cloning vector. The cloned product was sequenced in both directions using the automated ABI Prism 370 Sequencer.
Primer extension analysis
Primer extension analyses were done with GeneRacert Kit (Invitrogen) according to the manufacturer's instructions. Briefly, an 18-base oligonucleotide complementary to the position of À97 to À114 bp relative to the translation starting site of the human A33 gene was end-labeled with g 32 P[ATP] using T4 polynucleotide kinase. A quantity of 100 mg of total RNA from human LoVo cells isolated with the RNeasy Mini kit (Qiagen) was annealed to 10 6 c.p.m. of the primer and extended with 200 U of Superscript II reverse transcriptase. The resultant products were analysed on 7 m urea, 6% polyacrylamide gels in parallel with a DNA marker.
Construction of reporter genes driven by the 5
0 -fIanking region of A33 antigens DNA fragments representing different lengths of the A33 antigen gene 5 0 -flanking region were cloned upstream of the EGFP coding sequence in the pEGFP-1 vector (Clontech). The resultant plasmid is designated as pA33-EGFP.
Transient transfection
Human cell lines LoVo, BGC823, and 293 were cultured in DMEM supplemented with 10% fetal bovine serum for 24 h before being transfected with A33 antigen gene 5 0 -flanking region-driven EGFP reporter gene or the promoter-less pEGFP-1 vector plus a LacZ construct (pCMVb; Clontech) using Effectene Transfection Reagent (Qiagen). At 48 h after transfection, cells were harvested and lysed in 1 ml of reporter lysis buffer and EGFP activity was measured by photomicrographs. The fluorescence activity was normalized to bgalactosidase activity which was measured using the bgalactosidase Enzyme Assay System provided by Promega.
DNase I footprinting
Nuclear extracts were prepared by collecting cells in cold buffer A (10 mm HEPES, pH 7.9, 1.5 mm MgCl 2 , 10 mm KCl, 0.5 mm dithiothreitol, and 0.2 mm phenylmethylsulfonyl fluoride) and incubating on ice for 10 min. Cells were then frozen and thawed once and vortexed briefly. Nuclei were pelleted by brief centrifugation and resuspended in cold buffer C (20 mm HEPES, pH 7.9, 25% glycerol, 420 mm NaCl, 1.5 mm MgCl 2 , 0.2 mm EDTA, 0.5 mm dithiothreitol, and 0.2 mm phenylmethylsulfonyl fluoride) followed by incubation on ice for 30 min. The samples were then briefly centrifuged to remove debris and the supernatant was collected and stored at À801C. DNase I footprinting experiments were performed with a fragment corresponding to À140 to þ 25 of the A33 gene transcription starting site. This fragment was labeled with a 32 p[dATP] and incubated with nuclear extracts at room temperature for 30 min in a reaction mixture containing 4% glycerol, 10 mm Tris-HCl, pH 7.5, 50 mm NaCl, 2.5 mm MgCl 2 , 0.5 mm dithiothreitol, and 2 mg poly(dI:dC). After incubation, 2 U of DNase I was added and incubation was continued for exactly 1 min. Footprinting was done using a SureTrack Footprinting Kit from Amersham Biosciences (Piscataway, NJ, USA) according to the manufacturer's instructions. The samples were analysed on a 6% acrylamide/7 m urea denaturing gel.
Site-directed mutagenesis
Substitution mutations for nucleotides at positions À81 and À82 (CC-AG) and at positions À28, À29, and À30 (TAT-CGA) of the 5 0 -flanking region of A33 gene were generated using the QuikChange Mutagenesis Kit (Stratagene, La Jolla, CA, USA) according to the manufacturer's instructions. Synthetic oligonucleotides containing the desired bases were used in the mutagenesis and the sequences of these oligonucleotides were (CC-AG mutation: 5 0 -GCAAAT ATGGGCAACAAGCTTCTTTTACTAGCTTGG-3 0 and TAT-CGA mutation: 5 0 -GCATTTCCCTTTTTATCGAT-TATTTCCTGTCAGTTA-3 0 ). DNAs that incorporated the desired mutations were transformed into Epicurian Coli XL1-blue supercompetent cells. Plasmid DNAs were prepared and the presence of the mutations was confirmed by sequencing.
Electrophoretic mobility shift assays g 32 P end-labeled double-strand oligonucleotide (0.25 pmol) was mixed with 10 mg of nuclear extract in a final volume of 20 ml containing 10 mm Tris-HCl, pH 7.5, 100 mm NaCl, 3 mm MgCl 2 , 0.5 mm EDTA, 1 mm dithiothreitol, 5% glycerol, 2 mg of poly(dI:dC), 4 mm spermidine, and 1 mg of bovine serum albumin. Samples were incubated at 301C for 30 min. The reaction was conducted in the absence or presence of specific or nonspecific competitors, both added at a 50-fold molar excess. Specific competitors were cold probes and nonspecific competitors were an unrelated oligonucleotide. The DNAprotein complexes were analysed by electrophoresis on 6% nondenaturing polyacrylamide gels. The sequences of the oligonucleotides were as follows: probe A: 5 0 -GCAA-CACCCTTCTTTTACTAGC-3 0 , corresponding to the À86 to À68 and probe B: 5 0 -CCCTTTTTATTATTTATTTCCT-3 0 , corresponding to À40 to À19 region of the A33 antigen gene 5 0 -flanking region. For supershift assays, nuclear extracts and rabbit polyclonal anti-GKLF antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA, USA) were incubated for 30 min on ice prior to the addition of the radiolabeled probe.
Northern blot analysis and RT-PCR
Total RNA was isolated from cells using an RNeasy total RNA kit (Qiagen). DNA fragments from GKLF cDNA and b-actin cDNA were labeled with a 32 P[dCTP] using a randompriming kit (Promega). A quantity of 30 mg of total RNA from each sample was electrophoresed on 1% agrose/2.2 m formaldehyde gels. The RNA was then transferred to nylon membranes and crosslinked by UV exposure. Blots were hybridized using Expresshybt Hybridization solution (Clontech) and autoradiographed.
RT-PCR was performed by using a Qiagen OneStep RT-PCR Kit (Qiagen). Briefly, 1 mg of total RNA was subjected to reverse transcription at 501C for 30 min. Reactions were stopped by heating at 951C for 15 min. PCR products were analysed using 1.2% agarose gel electrophoresis and visualized with ethidium bromide staining. The forward primer was 5 0 -GCTTCGCAGGGAAAGA-3 0 from exon 2 of the A33 antigen gene and the reverse primer was 5 0 -CGATGCCCA-CATACAGG-3 0 from exon 6. GAPDH amplification was performed as an internal control. The primers for GAPDH amplification were: forward, 5 0 -ACCACAGTCCATGCCAT-CAC-3 0 and reverse, 5 0 -TCCACCACCCTGTTGCTGTA-3 0 .
Generation of the GKLF sense and anti-sense expression constructs
Full-length cDNA of human GKLF was obtained by RT-PCR and cloned into pcRII-Topo vector (Invitrogen). The sequence of the GKLF cDNA was then confirmed and subcloned in right orientation (for sense construct) or reverse orientation (for antisense construct) into pcDNA3.1( þ ) vector (Invitrogen). The sequence of the inserts was confirmed by sequencing.
Abbreviations GKLF, gut-enriched Kru¨ppel-like factor; EGFP, enhanced green fluorescent protein; EMSA, electrophoretic mobility shift assays.
